103.13MMarket Cap-802P/E (TTM)
0.996High0.875Low4.20MVolume0.905Open0.870Pre Close4.04MTurnover4.25%Turnover RatioLossP/E (Static)107.13MShares3.33052wk High1.99P/B95.26MFloat Cap0.67252wk Low--Dividend TTM98.95MShs Float35.200Historical High--Div YieldTTM13.90%Amplitude0.672Historical Low0.960Avg Price1Lot Size
Gritstone Bio Stock Forum
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...
Update! Like! Watching!
No comment yet